Manager TitleAgeSince
Corporate Secretary 60 07/08/2019
Director TitleAgeSince
Director/Board Member 60 06/06/2019
Director/Board Member 49 20/04/2020
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 0
-1.06%+9.92%+59.12%+68.61% 68.32B
+1.30%+10.98%+17.47%+92.69% 60.26B
+0.39%+1.75%+24.27%+98.33% 55.86B
-0.94%+11.43%+22.49%+111.69% 48.43B
-0.28%+4.70%+26.39%+42.61% 45.34B
-5.55%-8.77%+184.32%+827.18% 41.76B
+1.97%+9.00%+25.20%+50.98% 34.5B
-0.56%-4.25%+89.87%+65.40% 33.8B
-1.49%+13.52%+43.09%+0.06% 25.96B
Average -0.56%+4.29%+54.69%+150.84% 46B
Weighted average by Cap. -0.54%+4.03%+51.80%+148.75%
Logo Nightstar Therapeutics PLC
Nightstar Therapeutics PLC, formerly Nightstar Therapeutics Limited, is a clinical-stage gene therapy company. The Company is focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. The Company is developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases. The Company's lead product candidate, NSR-REP1, for the treatment of choroideremia, or CHM, is entering Phase III clinical development. The Company is also conducting a Phase I/II clinical trial with its second product candidate, NSR-RPGR, for the treatment of X-linked retinitis pigmentosa, or XLRP. The Company's third product candidate, NSR-BEST1, is in preclinical development for the treatment of Best vitelliform macular dystrophy, or Best disease.
Employees
-